Nomura Asset Management
MRNA icon

Nomura Asset Management’s Moderna MRNA Stock Holding History

Nomura Asset Management’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.23M Buy
17,502
+3,084
+21% +$160K ﹤0.01% 737
2026
Q1 		$732K Sell
14,418
-2,471
-15% -$115K ﹤0.01% 785
2025
Q4 		$498K Buy
16,889
+60
+0.4% +$1.63K ﹤0.01% 815
2025
Q3 		$435K Buy
16,829
+845
+5% +$23.6K ﹤0.01% 825
2025
Q2 		$441K Sell
15,984
-90,799
-85% -$2.39M ﹤0.01% 817
2025
Q1 		$3.03M Buy
106,783
+6,603
+7% +$234K 0.01% 671
2024
Q4 		$4.17M Sell
100,180
-14,155
-12% -$677K 0.01% 616
2024
Q3 		$7.64M Buy
114,335
+1,635
+1% +$150K 0.02% 475
2024
Q2 		$13.4M Sell
112,700
-7,779
-6% -$984K 0.05% 321
2024
Q1 		$12.8M Buy
120,479
+3,226
+3% +$325K 0.05% 328
2023
Q4 		$11.7M Sell
117,253
-2,769
-2% -$233K 0.05% 337
2023
Q3 		$12.4M Buy
120,022
+552
+0.5% +$61.6K 0.06% 303
2023
Q2 		$14.5M Sell
119,470
-4,567
-4% -$609K 0.07% 279
2023
Q1 		$19M Sell
124,037
-821
-0.7% -$135K 0.1% 236
2022
Q4 		$22.4M Buy
124,858
+1,522
+1% +$249K 0.13% 178
2022
Q3 		$14.6M Sell
123,336
-9,607
-7% -$1.46M 0.09% 244
2022
Q2 		$19M Sell
132,943
-490
-0.4% -$70K 0.12% 190
2022
Q1 		$23M Sell
133,433
-15,603
-10% -$2.63M 0.13% 169
2021
Q4 		$37.9M Buy
149,036
+72,641
+95% +$21.2M 0.19% 112
2021
Q3 		$29.4M Sell
76,395
-10,193
-12% -$3.76M 0.17% 133
2021
Q2 		$20.3M Buy
86,588
+11,038
+15% +$1.97M 0.12% 187
2021
Q1 		$9.89M Buy
75,550
+6,735
+10% +$976K 0.06% 301
2020
Q4 		$7.19M Sell
68,815
-8,798
-11% -$890K 0.05% 331
2020
Q3 		$5.49M Sell
77,613
-15,587
-17% -$1.09M 0.04% 352
2020
Q2 		$5.99M Buy
93,200
+64,200
+221% +$3.52M 0.05% 308
2020
Q1 		$869K Buy
+29,000
New +$667K 0.01% 724

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Nomura Asset Management's MRNA Position: Q2 2026 in Review

Nomura Asset Management increased its Moderna (MRNA) stake by 21% in Q2 2026, buying an estimated $160K and bringing the position to 17,502 shares worth $1.23M. The position accounts for ﹤0.01% of the portfolio, ranked #737.

Nomura Asset Management first reported a position in MRNA in Q1 2020 and has held it in 26 quarters since. The position peaked at $37.9M in Q4 2021. 777 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • Nomura Asset Management held 17,502 shares of Moderna worth $1.23M as of Q2 2026.
  • Nomura Asset Management bought 3,084 Moderna shares in Q2 2026, an estimated $160K.
  • Moderna made up ﹤0.01% of Nomura Asset Management's portfolio in Q2 2026, its #737 holding.
  • Nomura Asset Management first reported a position in Moderna in Q1 2020 and has held it in 26 quarters since.
  • Nomura Asset Management's Moderna position peaked at $37.9M in Q4 2021.
  • 777 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Nomura Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.